Odolini Silvia, Lanza Paola, Angiola Angiola, Zaltron Serena, Urbinati Lucia, Vavassori Andrea, Nasta Paola, Festa Elena, Gargiulo Franco, Rodella Anna, Caruso Arnaldo, Casari Salvatore, Castelli Francesco, Viganò Mauro
Clinic of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy.
Laboratory of Microbiology, Brescia Spedali Civili General Hospital, Brescia, Italy.
New Microbiol. 2017 Jul;40(3):218-220. Epub 2017 May 17.
Reactivation of the hepatitis B virus (HBV) has been reported in patients with occult infection (OBI), i.e. HBV surface antigen (HBsAg) negative, HBV core antibody (anti-HBc) positive ± antibodies against HBsAg (anti-HBs) and detectable HBV DNA in serum or liver, receiving immunosuppressive or cytotoxic therapies. Recently, concerns have been raised regarding the risk of HBV reactivation in OBI patients treated with direct acting antiviral agents (DAAs) for chronic hepatitis C (CHC). Here we describe a case of HBV reactivation in a 72-year-old woman with OBI as a possible consequence of effective treatment with sofosbuvir (SOF) and ribavirin (Rbv) for genotype 2a/2c CHC.
据报道，在隐匿性感染（OBI）患者中，即乙肝表面抗原（HBsAg）阴性、乙肝核心抗体（抗-HBc）阳性±乙肝表面抗原抗体（抗-HBs）且血清或肝脏中可检测到乙肝病毒DNA的患者，接受免疫抑制或细胞毒性治疗时会出现乙肝病毒（HBV）再激活。最近，对于接受直接抗病毒药物（DAA）治疗慢性丙型肝炎（CHC）的OBI患者发生HBV再激活的风险也引起了关注。在此，我们描述了一例72岁隐匿性乙肝感染女性患者出现HBV再激活的病例，这可能是索磷布韦（SOF）和利巴韦林（Rbv）有效治疗2a/2c基因型CHC的结果。
